Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease
Autosomal dominant polycystic kidney disease (ADPKD) is a leading genetic cause of end-stage renal disease with limited treatment options. Here the authors discover and characterize a microRNA inhibitor as a potential treatment for ADPKD.
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2019
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/bbe08759988a47b08a2411574e862c56 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:bbe08759988a47b08a2411574e862c56 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:bbe08759988a47b08a2411574e862c562021-12-02T14:40:00ZDiscovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease10.1038/s41467-019-11918-y2041-1723https://doaj.org/article/bbe08759988a47b08a2411574e862c562019-09-01T00:00:00Zhttps://doi.org/10.1038/s41467-019-11918-yhttps://doaj.org/toc/2041-1723Autosomal dominant polycystic kidney disease (ADPKD) is a leading genetic cause of end-stage renal disease with limited treatment options. Here the authors discover and characterize a microRNA inhibitor as a potential treatment for ADPKD.Edmund C. LeeTania ValenciaCharles AllersonAnnelie SchairerAndrea FlatenMatanel YheskelKara KersjesJian LiSole GattoMandeep TakharSteven LocktonAdam PavlicekMichael KimTiffany ChuRandy SorianoScott DavisJohn R. AndrosavichSalma SarwaryTate OwenJulia KaplanKai LiuGraham JangSteven NebenPhilip BentleyTimothy WrightVishal PatelNature PortfolioarticleScienceQENNature Communications, Vol 10, Iss 1, Pp 1-14 (2019) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Science Q |
| spellingShingle |
Science Q Edmund C. Lee Tania Valencia Charles Allerson Annelie Schairer Andrea Flaten Matanel Yheskel Kara Kersjes Jian Li Sole Gatto Mandeep Takhar Steven Lockton Adam Pavlicek Michael Kim Tiffany Chu Randy Soriano Scott Davis John R. Androsavich Salma Sarwary Tate Owen Julia Kaplan Kai Liu Graham Jang Steven Neben Philip Bentley Timothy Wright Vishal Patel Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease |
| description |
Autosomal dominant polycystic kidney disease (ADPKD) is a leading genetic cause of end-stage renal disease with limited treatment options. Here the authors discover and characterize a microRNA inhibitor as a potential treatment for ADPKD. |
| format |
article |
| author |
Edmund C. Lee Tania Valencia Charles Allerson Annelie Schairer Andrea Flaten Matanel Yheskel Kara Kersjes Jian Li Sole Gatto Mandeep Takhar Steven Lockton Adam Pavlicek Michael Kim Tiffany Chu Randy Soriano Scott Davis John R. Androsavich Salma Sarwary Tate Owen Julia Kaplan Kai Liu Graham Jang Steven Neben Philip Bentley Timothy Wright Vishal Patel |
| author_facet |
Edmund C. Lee Tania Valencia Charles Allerson Annelie Schairer Andrea Flaten Matanel Yheskel Kara Kersjes Jian Li Sole Gatto Mandeep Takhar Steven Lockton Adam Pavlicek Michael Kim Tiffany Chu Randy Soriano Scott Davis John R. Androsavich Salma Sarwary Tate Owen Julia Kaplan Kai Liu Graham Jang Steven Neben Philip Bentley Timothy Wright Vishal Patel |
| author_sort |
Edmund C. Lee |
| title |
Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease |
| title_short |
Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease |
| title_full |
Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease |
| title_fullStr |
Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease |
| title_full_unstemmed |
Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease |
| title_sort |
discovery and preclinical evaluation of anti-mir-17 oligonucleotide rgls4326 for the treatment of polycystic kidney disease |
| publisher |
Nature Portfolio |
| publishDate |
2019 |
| url |
https://doaj.org/article/bbe08759988a47b08a2411574e862c56 |
| work_keys_str_mv |
AT edmundclee discoveryandpreclinicalevaluationofantimir17oligonucleotidergls4326forthetreatmentofpolycystickidneydisease AT taniavalencia discoveryandpreclinicalevaluationofantimir17oligonucleotidergls4326forthetreatmentofpolycystickidneydisease AT charlesallerson discoveryandpreclinicalevaluationofantimir17oligonucleotidergls4326forthetreatmentofpolycystickidneydisease AT annelieschairer discoveryandpreclinicalevaluationofantimir17oligonucleotidergls4326forthetreatmentofpolycystickidneydisease AT andreaflaten discoveryandpreclinicalevaluationofantimir17oligonucleotidergls4326forthetreatmentofpolycystickidneydisease AT matanelyheskel discoveryandpreclinicalevaluationofantimir17oligonucleotidergls4326forthetreatmentofpolycystickidneydisease AT karakersjes discoveryandpreclinicalevaluationofantimir17oligonucleotidergls4326forthetreatmentofpolycystickidneydisease AT jianli discoveryandpreclinicalevaluationofantimir17oligonucleotidergls4326forthetreatmentofpolycystickidneydisease AT solegatto discoveryandpreclinicalevaluationofantimir17oligonucleotidergls4326forthetreatmentofpolycystickidneydisease AT mandeeptakhar discoveryandpreclinicalevaluationofantimir17oligonucleotidergls4326forthetreatmentofpolycystickidneydisease AT stevenlockton discoveryandpreclinicalevaluationofantimir17oligonucleotidergls4326forthetreatmentofpolycystickidneydisease AT adampavlicek discoveryandpreclinicalevaluationofantimir17oligonucleotidergls4326forthetreatmentofpolycystickidneydisease AT michaelkim discoveryandpreclinicalevaluationofantimir17oligonucleotidergls4326forthetreatmentofpolycystickidneydisease AT tiffanychu discoveryandpreclinicalevaluationofantimir17oligonucleotidergls4326forthetreatmentofpolycystickidneydisease AT randysoriano discoveryandpreclinicalevaluationofantimir17oligonucleotidergls4326forthetreatmentofpolycystickidneydisease AT scottdavis discoveryandpreclinicalevaluationofantimir17oligonucleotidergls4326forthetreatmentofpolycystickidneydisease AT johnrandrosavich discoveryandpreclinicalevaluationofantimir17oligonucleotidergls4326forthetreatmentofpolycystickidneydisease AT salmasarwary discoveryandpreclinicalevaluationofantimir17oligonucleotidergls4326forthetreatmentofpolycystickidneydisease AT tateowen discoveryandpreclinicalevaluationofantimir17oligonucleotidergls4326forthetreatmentofpolycystickidneydisease AT juliakaplan discoveryandpreclinicalevaluationofantimir17oligonucleotidergls4326forthetreatmentofpolycystickidneydisease AT kailiu discoveryandpreclinicalevaluationofantimir17oligonucleotidergls4326forthetreatmentofpolycystickidneydisease AT grahamjang discoveryandpreclinicalevaluationofantimir17oligonucleotidergls4326forthetreatmentofpolycystickidneydisease AT stevenneben discoveryandpreclinicalevaluationofantimir17oligonucleotidergls4326forthetreatmentofpolycystickidneydisease AT philipbentley discoveryandpreclinicalevaluationofantimir17oligonucleotidergls4326forthetreatmentofpolycystickidneydisease AT timothywright discoveryandpreclinicalevaluationofantimir17oligonucleotidergls4326forthetreatmentofpolycystickidneydisease AT vishalpatel discoveryandpreclinicalevaluationofantimir17oligonucleotidergls4326forthetreatmentofpolycystickidneydisease |
| _version_ |
1718390439894056960 |